SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
Description
The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses and the development of new variant-derived vaccines^(1-4). SARS-CoV-2 booster
